Varghese v. China Shenghuo Pharmaceutical Holdings, Inc.

589 F. Supp. 2d 388, 2008 U.S. Dist. LEXIS 101517, 2008 WL 5245360
CourtDistrict Court, S.D. New York
DecidedDecember 10, 2008
Docket08 Civ. 7422(VM)
StatusPublished
Cited by102 cases

This text of 589 F. Supp. 2d 388 (Varghese v. China Shenghuo Pharmaceutical Holdings, Inc.) is published on Counsel Stack Legal Research, covering District Court, S.D. New York primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Varghese v. China Shenghuo Pharmaceutical Holdings, Inc., 589 F. Supp. 2d 388, 2008 U.S. Dist. LEXIS 101517, 2008 WL 5245360 (S.D.N.Y. 2008).

Opinion

DECISION AND ORDER

VICTOR MARRERO, District Judge.

By motion dated October 22, 2008, plaintiff William R. Bennett (“Bennett”) moved the Court (1) to be appointed lead plaintiff in this action; and (2) to approve his choice of counsel, Cohen, Milstein, Sellers & Toll, P.L.L.C. (“Cohen Milstein”), as lead counsel for all plaintiffs in the proposed class (the “Class”). Also by motion dated October 22, 2008, plaintiffs Matthew Chia-Yiu Maa (“Maa”), David Dai, Shawn Rad, and Mohammad Khan (collectively, the “Maa Group”), moved the Court (1) to individually and collectively be appointed lead plaintiffs; and (2) to approve their choice of counsel, The Rosen Law Firm, P.A. (“Rosen”), as lead counsel. Finally, by motion dated October 22, 2008, Gordon Chace (“Chace”) moved the Court (1) to be appointed lead plaintiff; and (2) to approve his choice of counsel, Johnson Bottini, LLP, as lead counsel. For the reasons stated below, Bennett’s motion is GRANTED, and the Maa Group’s and Chace’s motions are DENIED.

I. BACKGROUND 1

The claims in this class action arise out of alleged violations of federal securities laws by defendant China Shenghuo Pharmaceutical Holdings, Inc. (“CSP”) between July 23, 2007 and August 20, 2008 (the “Class Period”).

CSP develops products derived from herbs to treat a myriad of health conditions, ranging from cardiovascular disease to the common cold. CSP is a publicly held company whose common stock (1) was and is registered with the United States Securities and Exchange Commission (“SEC”); (2) was traded on the American Stock Exchange (“AMEX”) until August 20, 2008; and (3) was and is governed by United States federal securities law.

On August 20, 2008, CSP issued a press release stating that its financial statements *391 for the periods ended June 30, September 30, and December 30, 2007, and the fiscal quarter ended March 31, 2008, contained accounting errors and should not be relied on until CSP issued a financial restatement for those quarters. This disclosure allegedly prompted CSP common stock to lose 19 percent of its value on that day, closing at $1.89 per share. The AMEX halted the sale of the stock at closing on August 20, 2008, and trading on CSP common stock currently remains halted.

In a complaint dated August 21, 2008 and filed in this Court, plaintiff Beno Varghese (“Varghese”), individually and on behalf of all others similarly situated, alleges that CSP’s actions during the Class Period violated §§ 10(b) and 20(a) of the Securities Exchange Act, 15 U.S.C. §§ 78j(b), 78t(a), and Rule 10b-5 promulgated thereunder, resulting in damages to himself and others in the Class. 2 On August 23, 2008, Varghese’s counsel issued a notice (the “Notice”) informing potential Class members of: (1) the allegations and claims contained in the Complaint; (2) the purported Class Period; and (3) their opportunity to move the Court to serve as lead plaintiff within sixty days, pursuant to the Private Securities Litigation Reform Act of 1995 (“PSLRA”). Class members Bennett, the Maa Group, and Chace each moved the Court for appointment as lead plaintiff(s) and to have their respective choice of counsel approved as lead counsel.

II. DISCUSSION

A.LEGAL STANDARD

The PSLRA provides the standard for selecting a lead plaintiff in class actions brought pursuant to the Securities Exchange Act. The PSLRA directs that:

the court shall adopt a presumption that the most adequate plaintiff in any private action arising under this chapter is the person or group of persons that—
(aa) has either filed the complaint or made a motion in response to a notice
(bb) in the determination of the court, has the largest financial interest in the relief sought by the class; and
(cc) otherwise satisfies the requirements of Rule 23 of the Federal Rules of Civil Procedure.

15 U.S.C. § 78u — 4(a)(3)(B)(iii)(I).

The Court’s identification of the presumptively most adequate lead plaintiff may be rebutted if class members offer evidence that the presumptive lead plaintiff: (1) “will not fairly and adequately protect the interests of the class”; or (2) “is subject to unique defenses that render such plaintiff incapable of adequately representing the class.” Id. § 78u-4(a)(3)(B)(iii)(II).

B. THE MOTIONS UNDER CONSIDERATION ARE TIMELY

Varghese published the Notice on August 23, 2008. Bennett, the Maa Group, and Chace filed their respective motions on October 22, 2008. The movants’ motions all satisfy the requirement that such motions be filed within sixty days of the Notice’s publication. See id. § 78Ü-4 (a)(3)(A)(i)(II). All three movants therefore satisfy § 78u-4(a)(3)(B)(iii)(I)(aa).

C. BENNETT HAS THE LARGEST FINANCIAL INTEREST IN THE RELIEF SOUGHT BY THE CLASS

1. The Maa Group Is Not an Appropriate Candidate for a Group of Lead Plaintiffs

Though the PSLRA expressly permits a “person or group of persons” to be ap *392 pointed lead plaintiff, 15 U.S.C. § 78u-4(a)(3)(b)(iii)(I), the PSLRA does not define what a “group” can or should be, nor how its “members” must be related to one another. See In re eSpeed, Inc. Sec. Litig., 232 F.R.D. 95, 99 (S.D.N.Y.2005) (“[T]he [PSLRA] does not specify whether the ‘members’ must be related in some fashion ip order to qualify as an appropriate lead plaintiff group.”).

Historically, district courts have been divided over whether a group of unrelated investors constitutes a “group of persons” that may be appointed lead plaintiff. See id.; In re Star Gas Sec. Litig., No. 3:04 CV 1766, 2005 WL 818617, at *4 (D.Conn. Apr. 8, 2005) (noting that some courts forbid the aggregation of unrelated plaintiffs while other courts accept a proposed group of lead plaintiffs without scrutiny). The majority of courts, including those in this District, have adopted an intermediate position, permitting unrelated investors to join together as a group seeking lead-plaintiff status on a case-by-case basis, if such a grouping would best serve the class. See, e.g., In re Oxford Health Plans, Inc. Sec. Litig., 182 F.R.D. 42, 49 (S.D.N.Y.1998) (“Because the PSLRA does not recommend or delimit a specific number of lead plaintiffs, the lead plaintiff decision must be made on a case-by-case basis, taking account of the unique circumstances of each case.”).

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Cite This Page — Counsel Stack

Bluebook (online)
589 F. Supp. 2d 388, 2008 U.S. Dist. LEXIS 101517, 2008 WL 5245360, Counsel Stack Legal Research, https://law.counselstack.com/opinion/varghese-v-china-shenghuo-pharmaceutical-holdings-inc-nysd-2008.